Patrick Darken

2.9k total citations · 1 hit paper
73 papers, 1.8k citations indexed

About

Patrick Darken is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology and Allergy. According to data from OpenAlex, Patrick Darken has authored 73 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pulmonary and Respiratory Medicine, 43 papers in Physiology and 6 papers in Immunology and Allergy. Recurrent topics in Patrick Darken's work include Chronic Obstructive Pulmonary Disease (COPD) Research (52 papers), Asthma and respiratory diseases (43 papers) and Inhalation and Respiratory Drug Delivery (37 papers). Patrick Darken is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (52 papers), Asthma and respiratory diseases (43 papers) and Inhalation and Respiratory Drug Delivery (37 papers). Patrick Darken collaborates with scholars based in United States, United Kingdom and Germany. Patrick Darken's co-authors include Colin Reisner, Gary T. Ferguson, Paul Dorinsky, Klaus F. Rabe, Shaila Ballal, Magnus Aurivillius, Chen Wang, Fernando J. Martínez, Earl St. Rose and Roopa Trivedi and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Patrick Darken

70 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

2020 374 citations Klaus F. Rabe, Gary T. Ferguson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Darken United States	18	1.6k	1.3k	105	57	56	73	1.8k
Donald Banerji United States	29	3.8k 2.4×	3.2k 2.5×	150 1.4×	65 1.1×	89 1.6×	155	4.0k
Filip Mejza Poland	16	402 0.3×	486 0.4×	45 0.4×	35 0.6×	59 1.1×	31	852
George Visick United Kingdom	7	756 0.5×	457 0.4×	33 0.3×	104 1.8×	68 1.2×	8	964
Anthony E. Camilli United States	14	810 0.5×	443 0.4×	15 0.1×	79 1.4×	43 0.8×	16	1.1k
Silvia Tognella Italy	19	684 0.4×	542 0.4×	102 1.0×	69 1.2×	39 0.7×	56	904
Lisa Willits United Kingdom	11	1.9k 1.2×	1.2k 1.0×	11 0.1×	162 2.8×	92 1.6×	16	2.1k
Gerald L. Strope United States	14	518 0.3×	379 0.3×	24 0.2×	75 1.3×	16 0.3×	20	920
Sami Saarelainen Finland	15	603 0.4×	542 0.4×	35 0.3×	47 0.8×	36 0.6×	22	971
P. Paggiaro Italy	14	247 0.2×	240 0.2×	89 0.8×	32 0.6×	19 0.3×	24	633
Zöe Borrill United Kingdom	15	752 0.5×	528 0.4×	16 0.2×	45 0.8×	32 0.6×	20	1.0k

Countries citing papers authored by Patrick Darken

Since Specialization

Citations

This map shows the geographic impact of Patrick Darken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Darken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Darken more than expected).

Fields of papers citing papers by Patrick Darken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Darken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Darken. The network helps show where Patrick Darken may publish in the future.

Co-authorship network of co-authors of Patrick Darken

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Darken. A scholar is included among the top collaborators of Patrick Darken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Darken. Patrick Darken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Muro, Shigeo, John R. Hurst, Jonathan Marshall, et al.. (2024). Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS. International Journal of COPD. Volume 19. 2729–2737.

Singh, Dave, John R. Hurst, Fernando J. Martínez, et al.. (2022). Predictive modeling of COPD exacerbation rates using baseline risk factors. Therapeutic Advances in Respiratory Disease. 16. 2673686642–2673686642. 14 indexed citations

Martínez, Fernando J., Gary T. Ferguson, Eric Bourne, et al.. (2021). Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS. International Journal of COPD. Volume 16. 179–189. 11 indexed citations

Muro, Shigeo, Hisatoshi Sugiura, Patrick Darken, & Paul Dorinsky. (2021). Correction to: Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts. Respiratory Research. 22(1). 1 indexed citations

Dorinsky, Paul, et al.. (2020). The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline. SHILAP Revista de lepidopterología. 1 indexed citations

Ferguson, Gary T., Patrick Darken, Shaila Ballal, et al.. (2020). Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. Advances in Therapy. 37(6). 2956–2975. 17 indexed citations

Martínez, Fernando J., Klaus F. Rabe, Gary T. Ferguson, et al.. (2020). Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. American Journal of Respiratory and Critical Care Medicine. 203(5). 553–564. 147 indexed citations

Rabe, Klaus F., Fernando J. Martínez, Gary T. Ferguson, et al.. (2020). Single-Inhaler Triple Combination Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) at Two Corticosteroid Dose Levels in COPD: ETHOS Trial. A2493–A2493. 1 indexed citations

Rabe, Klaus F., Fernando J. Martínez, Gary T. Ferguson, et al.. (2019). A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respiratory Medicine. 158. 59–66. 24 indexed citations

10.

Darken, Patrick, Paolo B. DePetrillo, Colin Reisner, Earl St. Rose, & Paul Dorinsky. (2018). The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults. Pulmonary Pharmacology & Therapeutics. 50. 11–18. 13 indexed citations

11.

Kerwin, Edward, Thomas M. Siler, Samir Arora, et al.. (2018). Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD. International Journal of COPD. Volume 13. 1483–1494. 2 indexed citations

12.

Fakih, Faisal, Selwyn Spangenthal, Barry Sigal, et al.. (2018). Randomized study of the effects of Aerochamber Plus® Flow-Vu® on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease. Respiratory Medicine. 138. 74–80. 10 indexed citations

13.

Reisner, Colin, Leonardo M. Fabbri, Edward Kerwin, et al.. (2017). A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respiratory Research. 18(1). 158–158. 21 indexed citations

14.

Martínez, Fernando J., Klaus F. Rabe, Gary T. Ferguson, et al.. (2016). Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. CHEST Journal. 151(2). 340–357. 94 indexed citations

15.

Quinn, Dean, J. Paul Seale, Colin Reisner, et al.. (2014). A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD. Respiratory Medicine. 108(9). 1327–1335. 10 indexed citations

16.

Reisner, Colin, Carlos Fernández‐Peña, Patrick Darken, et al.. (2014). Pearl's PT010 triple combination provides comparable budesonide exposure to symbicort and comparable glycopyrronium and formoterol exposure to PT003. European Respiratory Journal. 44(Suppl 58). 1891–1891. 3 indexed citations

17.

Fabbri, Leonardo M., et al.. (2013). Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators. European Respiratory Journal. 42(Suppl 57). P759–P759. 2 indexed citations

18.

Berger, William E., Anjuli Nayak, Bobby Q. Lanier, et al.. (2008). Efficacy and Safety of Once-Daily Ciclesonide Nasal Spray in Children With Allergic Rhinitis. Pediatric Asthma Allergy & Immunology. 21(2). 73–82. 9 indexed citations

19.

Ratner, Paul H., Patrick Darken, Mark A. Wingertzahn, & Tushar Shah. (2007). Ciclesonide and Beclomethasone Dipropionate Coadministration: Effect on Cortisol in Perennial Allergic Rhinitis. Journal of Asthma. 44(8). 629–633. 6 indexed citations

20.

Ratner, Paul H., et al.. (2006). Effectiveness of ciclesonide nasal spray in the treatment of seasonal allergic rhinitis. Annals of Allergy Asthma & Immunology. 97(5). 657–663. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact